Stemline Therapeutics, Inc. (NASDAQ:STML) had its price objective increased by HC Wainwright from $34.00 to $38.00 in a research note published on Wednesday, November 1st, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.
STML has been the topic of several other reports. Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 18th. ValuEngine cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 10th. Cowen and Company restated a buy rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. Finally, BidaskClub upgraded Stemline Therapeutics from a hold rating to a buy rating in a research note on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Stemline Therapeutics has a consensus rating of Buy and a consensus price target of $33.40.
Shares of Stemline Therapeutics (STML) traded up $0.10 during trading hours on Wednesday, reaching $14.10. The company’s stock had a trading volume of 250,800 shares, compared to its average volume of 280,453. Stemline Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $14.60.
ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics, Inc. (STML) PT Raised to $38.00 at HC Wainwright” was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/stemline-therapeutics-inc-stml-pt-raised-to-38-00/1748828.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in STML. FMR LLC raised its stake in shares of Stemline Therapeutics by 72.1% during the 1st quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock worth $21,708,000 after purchasing an additional 1,063,457 shares during the period. Lyon Street Capital LLC raised its stake in shares of Stemline Therapeutics by 331.1% during the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after purchasing an additional 415,867 shares during the period. Vanguard Group Inc. raised its stake in shares of Stemline Therapeutics by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock worth $7,055,000 after purchasing an additional 204,228 shares during the period. AXA raised its stake in shares of Stemline Therapeutics by 44.9% during the 2nd quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after purchasing an additional 195,022 shares during the period. Finally, C WorldWide Group Holding A S bought a new stake in Stemline Therapeutics in the 3rd quarter valued at about $1,776,000. Institutional investors own 49.01% of the company’s stock.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with our FREE daily email newsletter.